10 completed. 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 10 |
Follow asunaprevir: new trials by email Literature Review of asunaprevir trials Research Report on asunaprevir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV daclatasvir, asunaprevir, Ribavirin - Hepatitis C | Phase 3 | Completed | Kaohsiung Medical University Chung-Ho Memorial Hospital | 70 | 2016-11-01 | 2019-01-09 |
| A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection Daclatasvir, Asunaprevir - Hepatitis C | Phase 3 | Completed | Bristol-Myers Squibb | 207 | 2015-08-01 | 2017-04-19 |
| UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C Daclatasvir, Asunaprevir, DCV 3DAA - Hepatitis C Virus Infection | Phase 3 | Completed | Bristol-Myers Squibb | 297 | 2014-04-01 | 2015-09-18 |
| Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual Asunaprevir, Daclatasvir - Hepatitis C | Phase 3 | Completed | Bristol-Myers Squibb | 218 | 2014-02-28 | 2020-08-11 |
| Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients Daclatasvir, asunaprevir - Chronic Hepatitis C | Phase 3 | Completed | Foundation for Liver Research | 12 | 2014-02-01 | 2015-10-19 |
| UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis Daclatasvir, Asunaprevir, BMS-791325 - Hepatitis C | Phase 3 | Completed | Bristol-Myers Squibb | 202 | 2013-12-01 | 2015-10-09 |
| A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects Daclatasvir, Asunaprevir, Ribavirin - Hepatitis C Virus Infection | Phase 3 | Completed | Bristol-Myers Squibb | 258 | 2012-11-01 | 2015-10-09 |
| Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) Asunaprevir (ASV), Daclatasvir (DCV), Pegylated-interferon alfa 2a (PegIFN) - Hepatitis C Virus | Phase 3 | Completed | Bristol-Myers Squibb | 748 | 2012-05-01 | 2015-10-09 |
| Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) Asunaprevir, Daclatasvir, Peg-interferon Alfa-2a - Hepatitis C Virus | Phase 3 | Completed | Bristol-Myers Squibb | 398 | 2012-05-01 | 2015-10-09 |
| A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients BMS-790052 (Daclatasvir), BMS-650032 (Asunaprevir) - Hepatitis C | Phase 3 | Completed | Bristol-Myers Squibb | 224 | 2012-01-01 | 2015-10-09 |
Hepatitis C (9) · Hepatitis C, Chronic (1)
Bristol-Myers Squibb (8) · Foundation for Liver Research (1) · Kaohsiung Medical University Chung-Ho Memorial Hospital (1)
South Korea (4) · Taiwan (4) · Canada (3) · France (3) · Japan (3) · Netherlands (3) · Russia (3) · United States (3) · Argentina (2) · Australia (2) · China (2) · Germany (2) · Italy (2) · Spain (2) · Austria (1)
Ming-Lung Yu, MD., PhD. (1) · Rob de Knegt, M.D. (1)
PMID 26683763, PMID 24604476, PMID 25078304, PMID 25703086, PMID 25942724, PMID 26223768, PMID 27009831, PMID 27287851